1. Home
  2. TPC vs MLYS Comparison

TPC vs MLYS Comparison

Compare TPC & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tutor Perini Corporation

TPC

Tutor Perini Corporation

HOLD

Current Price

$70.01

Market Cap

3.1B

ML Signal

HOLD

Logo Mineralys Therapeutics Inc.

MLYS

Mineralys Therapeutics Inc.

HOLD

Current Price

$33.44

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TPC
MLYS
Founded
1894
2019
Country
United States
United States
Employees
N/A
N/A
Industry
General Bldg Contractors - Nonresidential Bldgs
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
3.1B
IPO Year
N/A
2023

Fundamental Metrics

Financial Performance
Metric
TPC
MLYS
Price
$70.01
$33.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
7
Target Price
$82.00
$47.33
AVG Volume (30 Days)
454.5K
1.5M
Earning Date
02-26-2026
02-11-2026
Dividend Yield
0.34%
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$5,103,323,000.00
N/A
Revenue This Year
$25.77
N/A
Revenue Next Year
$14.81
N/A
P/E Ratio
N/A
N/A
Revenue Growth
19.22
N/A
52 Week Low
$18.34
$8.24
52 Week High
$77.00
$47.65

Technical Indicators

Market Signals
Indicator
TPC
MLYS
Relative Strength Index (RSI) 55.58 29.64
Support Level $67.61 $34.21
Resistance Level $72.71 $37.70
Average True Range (ATR) 2.24 1.56
MACD 0.10 -0.13
Stochastic Oscillator 56.61 14.42

Price Performance

Historical Comparison
TPC
MLYS

About TPC Tutor Perini Corporation

Tutor Perini Corp offers general contracting, construction management, and design-build services to private and public customers. The company constructs and repairs transportation infrastructure, water-treatment facilities, and a wide range of buildings. Tutor Perini has three operating segments: Civil, Building, and Specialty Contractors. A majority of its revenue is generated from the Civil segment, which specializes in public works construction and the replacement and reconstruction of infrastructure. Its civil contracting services include construction and rehabilitation of highways, bridges, tunnels, mass-transit systems, military and other government facilities, and water management and wastewater treatment facilities. Geographically, it derives key revenue from the United States.

About MLYS Mineralys Therapeutics Inc.

Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.

Share on Social Networks: